Intuitive Surgical and Computer Motion Merge to Create Concentrated Robotics Play

Tired of fighting each other in court, the two leading robotics companies have decided to render their IP differences moot through a merger.

For many companies trying to get innovative technology accepted in the marketplace, intellectual property becomes a critical battleground. But when it becomes the primary battleground, IP litigation can divert and distort the companies from their main goal: gaining adoption for their technology. That, at least, is what happened in surgical robotics, a highly promising, but to date poorly penetrated innovation. And now, tired of fighting each other in court, the two leading robotics companies, Sunnyvale, CA-based Intuitive Surgical Inc. and Santa Barbara, CA-based Computer Motion Inc. , have decided to render their IP differences moot through a merger of the two companies [See Deal].

Discussing the deal, Lonnie Smith, Intuitive's CEO who will run the combined company, noted that "Clearly, we were both pouring a ton of time, energy, and resources into IP battles." And the continuing litigation was "a huge cash drain and not without risk for both companies," he went on. Even Intuitive felt the stress, though it had, of late, been faring better in its court battles—it won a summary judgment in a Delaware court last July over voice-control technology, which would have required Computer Motion to pay Intuitive a royalty, and more recently, the firm won a summary judgment motion in a California court. (Dismissal of the patent litigation on the part of Computer Motion is one of the conditions of the merger.) Indeed, in part because of the continuing litigation, Intuitive has been losing money and Computer Motion ran out of cash. The merger is, in some measure, recognition by executives from both companies that they needed to stop spending money on things other than product development and sales and marketing

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Innovation

ML-Assisted Genetic Risk Score Predicts GLP-1 Toxicity

 
• By 

Phenomix Science presented new data at Digestive Disease Week 2025 showing its machine learning-assisted genetic risk score can predict nausea and side effects from GLP-1 receptor agonists, aiding personalized obesity treatment.

The pre|CISION Approach: How Avacta Is Making Toxic Cancer Drugs Safe And More Effective

 
• By 

Avacta's approach to drug delivery is showing how 'masked' chemotherapy can dramatically improve safety profiles while maintaining or enhancing efficacy where it matters most.

Bringing Israeli Medical Device Candidates To The Right Partners In The US

 
• By 

Despite regional unrest, it is business as usual for medtech innovators and investors in Israel as evidenced by continued high-value M&A of locally developed technologies. Irit Yaniv, co-chair of the medtech session at the upcoming BioMed Israel 2025, explained the unique dynamics of Israeli medtech innovation.

Digital Transformation At The FDA: Generative AI Set To Transform Drug Review Process

 
• By 

The FDA plans to implement generative AI for drug reviews by 30 June 2025, enhancing efficiency and potentially accelerating approval processes. Discussions with OpenAI about AI integration are ongoing.

More from In Vivo

AI In Drug Discovery: The Patent Implications

 
• By 

A Q&A with DeAnn Smith, partner and co-chair of the Patent Trial and Appeal Board Proceedings Practice Group at law firm Foley Hoag.

The pre|CISION Approach: How Avacta Is Making Toxic Cancer Drugs Safe And More Effective

 
• By 

Avacta's approach to drug delivery is showing how 'masked' chemotherapy can dramatically improve safety profiles while maintaining or enhancing efficacy where it matters most.

Bringing Israeli Medical Device Candidates To The Right Partners In The US

 
• By 

Despite regional unrest, it is business as usual for medtech innovators and investors in Israel as evidenced by continued high-value M&A of locally developed technologies. Irit Yaniv, co-chair of the medtech session at the upcoming BioMed Israel 2025, explained the unique dynamics of Israeli medtech innovation.